SCHEMBL1574448

SCHEMBL1574448

COc1ccc(N2CCN(C3CN(C(=O)Nc4cc(C(F)(F)F)cc(C(F)(F)F)c4)C3)CC2)cc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.66
LMNA P02545 4/20 0.66
SMN1; SMN2 Q16637 3/20 0.57
HSD17B10 Q99714 2/20 0.57
GAA P10253 1/20 0.57
USP2 O75604 4/20 0.51
CYP3A4 P08684 4/20 0.51
ALDH1A1 P00352 2/20 0.49
CCNC P24863 1/20 0.49
CDK8 P49336 1/20 0.49
CYP2C9 P11712 1/20 0.49
HTR1A P08908 2/20 0.48
HTR1D P28221 2/20 0.48
HTR1B P28222 2/20 0.48
HTR2A P28223 1/20 0.48
HTR2C P28335 1/20 0.48
HTR6 P50406 1/20 0.48
S1PR2 O95136 1/20 0.48
CA12 O43570 2/20 0.48
CA1 P00915 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1574867 0.90 LMNA (0.61) MAPTLMNASMN1; SMN2HSD17B10GAA
SCHEMBL1574888 0.90 LMNA (0.52) MAPTLMNASMN1; SMN2HSD17B10GAA
SCHEMBL1574862 0.86 LMNA (0.57) MAPTLMNASMN1; SMN2HSD17B10GAA
SCHEMBL1575324 0.85 PRKAB2 (0.60) MAPTLMNAUSP2CYP3A4ALDH1A1
SCHEMBL1575220 0.85 MAPT (0.57) MAPTLMNASMN1; SMN2HSD17B10GAA
SCHEMBL1575426 0.85 LMNA (0.49) MAPTLMNASMN1; SMN2HSD17B10GAA
SCHEMBL1575176 0.82 LMNA (0.51) MAPTLMNASMN1; SMN2HSD17B10GAA
SCHEMBL1574330 0.82 MAPT (0.53) MAPTLMNAHSD17B10GAAUSP2
SCHEMBL1574951 0.82 LMNA (0.65) MAPTLMNASMN1; SMN2HSD17B10GAA
SCHEMBL1575243 0.81 SLC1A2 (0.63) MAPTLMNASMN1; SMN2HSD17B10GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2308562-A2 Azetidine ring compounds and drugs comprising the same Ono Pharmaceutical Co., Ltd. (JP) 2011-04-13 EP disclosed
US-7511159-B2 Azetidine ring compounds and drugs comprising the same ONO PHARMACEUTICAL CO., LTD. (JP) 2009-03-31 US disclosed
US-20070135402-A1 Azetidine ring compounds and drugs comprising the same ONO PHARMACEUTICAL CO., LTD. (JP) 2007-06-14 US disclosed
EP-1698375-A1 AZETIDINE RING COMPOUNDS AND DRUGS COMPRISING THE SAME ONO PHARMACEUTICAL CO., LTD. (JP) 2006-09-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135402-A1 Azetidine ring compounds and drugs comprising the same EDNRA, LIPG, EDNRB MAPT 3908/4885LMNA 1076/4885SMN1; SMN2 1838/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.